Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.
about
Withdrawal or continuation of cholinesterase inhibitors and/or memantine in patients with dementiaDrug development for Alzheimer's disease: where are we now and where are we headed?Donepezil in Alzheimer's disease: From conventional trials to pharmacogeneticsLatrepirdine, a potential novel treatment for Alzheimer's disease and Huntington's chorea.Pre- and post-synaptic cortical cholinergic deficits are proportional to amyloid plaque presence and density at preclinical stages of Alzheimer's diseaseNovel piperine-loaded Tween-integrated monoolein cubosomes as brain-targeted oral nanomedicine in Alzheimer's disease: pharmaceutical, biological, and toxicological studies.Alzheimer's Disease: Differences of Transdermal versus Oral Treatment on Caregiving Time.Rivastigmine in Alzheimer's disease: Cognitive function and quality of life.Pharmacotherapy of Alzheimer disease.Early identification and treatment of Alzheimer's disease: social and fiscal outcomes.Donepezil in the treatment of patients with Alzheimer's disease.Acute but not chronic donepezil increases muscarinic receptor-mediated signaling via arachidonic acid in unanesthetized rats.Nanomedicine for the treatment of Alzheimer's disease.Galantamine treatment in outpatients with mild Alzheimer's disease.Dose-dependent effects of ladostigil on microglial activation and cognition in aged rats.We can work it out: Group decision-making builds social identity and enhances the cognitive performance of care residents.Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts
P2860
Q24235324-0A4D0835-2B98-47F6-A22C-874365F1BD0EQ34166256-12C0CFBF-3C19-4835-8479-E0FD98448DD6Q34965949-9A8DFB69-AFAE-4240-86C7-6D2F1D98BCC1Q35940409-B0F95740-7912-4838-A800-99912737B680Q35995627-729D7EEE-554D-4D28-A3D7-49A475AE2355Q36015934-91EF3819-2CAC-4FA3-8FA7-5890ECA215D5Q36467267-424FF14F-1822-409D-9D82-A1921028DCEAQ36663678-6D5E3083-ED67-4CDB-B6D1-19B804CDCA1AQ37004359-6A4F498A-70C9-486B-B220-901821448C29Q37449105-55654E3D-CD40-4686-A81D-A92CFF2F9FB0Q37464161-6F5CBA77-BCA3-4694-806C-9DC9C5A86310Q37464280-8C49D36F-685E-4F78-B377-23D267BA2CF1Q38451932-84AE9E0E-F5CB-4B05-97A1-66B9688D9D0BQ42639500-F6782C18-8570-4E8D-A751-E466A13DF2FFQ45180137-4C9AF438-4B21-45AE-BA79-C2C483CABE01Q45738631-B831395A-9391-488A-9516-FA521FBE7317Q57271936-7E0E3C86-7A9D-4F70-A835-47737180A74E
P2860
Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh
2005年學術文章
@zh-hant
name
Cognitive performance in patie ...... inhibitors for up to 5 years.
@ast
Cognitive performance in patie ...... inhibitors for up to 5 years.
@en
type
label
Cognitive performance in patie ...... inhibitors for up to 5 years.
@ast
Cognitive performance in patie ...... inhibitors for up to 5 years.
@en
prefLabel
Cognitive performance in patie ...... inhibitors for up to 5 years.
@ast
Cognitive performance in patie ...... inhibitors for up to 5 years.
@en
P2860
P1476
Cognitive performance in patie ...... inhibitors for up to 5 years.
@en
P2093
P2860
P304
P356
10.1111/J.1368-5031.2005.00562.X
P577
2005-07-01T00:00:00Z